Nuclidium
Basel
About Nuclidium
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $104.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2025)
- Website: swissnuclides.ch
- Phone: +41 78 326 6666
Industries & Categories
Health Care, Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nuclidium-90678 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.